Skip to main content
MIRM
NASDAQ Life Sciences

Brelovitug Hits Primary Endpoint in Second Phase 3, Completing Registrational Package

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$93.18
Mkt Cap
$6.083B
52W Low
$63.232
52W High
$130
52W Position info
47% above low
Off High info
28% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

MIRM sits 47% above its 52-week low of $63.232.

Summary

Brelovitug met the primary endpoint in AZURE-4, the second of two Phase 3 studies that form Mirum's U.S. registration package for chronic hepatitis delta virus. The study enrolled 113 treatment-naive patients, 53% of them cirrhotic. At Week 24, 59% of patients on 300 mg weekly and 44% on 900 mg every four weeks achieved the combined virologic response and ALT normalization endpoint versus 0% in the delayed-treatment arm, with p≤0.0001 for both. Flu-like illness was the most common adverse event, at 17.2% with 300 mg weekly and 18.5% with 900 mg every four weeks, and there were no new safety signals. This follows the September AZURE-1 win and closes out the registrational data Mirum needs. The company plans a BLA submission in the first half of 2027 with a potential U.S. launch in Q4 2027. Long-term AASLD data showed deepening viral suppression and ALT normalization with extended treatment, including in patients with cirrhosis.

Updated with an SEC 8-K filing · What changed

Updates

  1. · SEC 8-K — AZURE-4 enrolled 113 treatment-naive patients (53% cirrhotic); flu-like illness was the most common adverse event at 17.2% (300 mg QW) and 18.5% (900 mg Q4W), with no new safety signals.

At the time of this announcement, MIRM was trading at $93.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $63.23 to $130.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

MIRM - Latest Insights

MIRM
Nov 10, 2026, 7:41 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $93.18
Real-time Price: $93.79 info
Change: +$0.605 (+0.65%) info
Market Cap: $6.122B info
MIRM
Nov 03, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $87.03
Real-time Price: $93.79 info
Change: +$6.75 (+8%) info
Market Cap: $6.122B info
MIRM
Nov 03, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $87.03
Real-time Price: $93.79 info
Change: +$6.75 (+8%) info
Market Cap: $6.122B info
MIRM
Nov 03, 2026, 4:01 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $87.03
Real-time Price: $93.79 info
Change: +$6.75 (+8%) info
Market Cap: $6.122B info
MIRM
Oct 26, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $80.15
Real-time Price: $93.79 info
Change: +$13.63 (+17%) info
Market Cap: $6.122B info